评估孕前甲状腺功能正常且甲状腺过氧化物酶抗体阳性女性进展为甲状腺功能减退症的情况
这项在49家英国医院开展的观察性队列研究纳入940例甲状腺功能正常且TPOAb阳性的计划妊娠女性,随机接受左甲状腺素50 mcg/日或安慰剂。7.4%在孕前或妊娠期发展为亚临床或临床甲减,左甲状腺素组与安慰剂组风险比为0.63(95%CI 0.39-1.00;P=0.05)。治疗后的甲减组受孕失败率高于甲状腺功能正常组,但活产率相似。
要点
- 甲状腺功能正常且TPOAb阳性的计划妊娠女性中,约7%在1年内进展为甲减。
- 左甲状腺素组甲减发生风险低于安慰剂组,但未达统计学显著。
- 治疗后的亚临床或临床甲减女性受孕失败率较高,活产率与甲状腺功能正常者相似。
核心结论
- 约7%的甲状腺功能正常且TPOAb阳性的女性在孕前1年内或妊娠期会发展为甲减。
- 与甲状腺功能正常女性相比,治疗后亚临床或临床甲减女性的受孕率较低,但活产率相当。
- 作者认为,TPOAb阳性女性在尝试受孕时应定期监测甲状腺功能,以确保及时诊断和适当治疗。
研究设计与样本
- 观察性队列研究,2011年至2016年在49家英国医院开展。
- 纳入940例16至40岁、有流产或生育力低下史、计划妊娠的甲状腺功能正常且TPOAb阳性女性。
- 参与者随机接受左甲状腺素50 mcg每日或安慰剂治疗。
主要发现
- 70/940(7.4%)发展为亚临床或临床甲减:左甲状腺素组27/470,安慰剂组43/470(相对风险[RR] 0.63;95%CI 0.39-1.00;P=0.05)。
- 83%的甲减病例发生在孕前。
- 发生甲减者与未发生者的基线血清TSH中位数和TPOAb滴度均显著更高(P<0.001)。
- 治疗后亚临床或临床甲减组受孕失败率高于甲状腺功能正常组(校正RR 2.02 [1.56-2.62];P<0.001)。
- 治疗后亚临床或临床甲减组与甲状腺功能正常组的活产率(≥34周)相似(校正RR 1.09 [0.77-1.55];P=0.6)。
关键数值与推荐
- 亚临床或临床甲减发生率:70/940(7.4%)。
- 左甲状腺素组 vs 安慰剂组甲减发生风险:RR 0.63(95%CI 0.39-1.00;P=0.05)。
- 治疗后亚临床或临床甲减组 vs 甲状腺功能正常组受孕失败率:校正RR 2.02(95%CI 1.56-2.62;P<0.001)。
- 治疗后亚临床或临床甲减组 vs 甲状腺功能正常组活产率(≥34周):校正RR 1.09(95%CI 0.77-1.55;P=0.6)。
临床怎么用
- 作者认为,TPOAb阳性女性在尝试受孕时应定期监测甲状腺功能,以确保及时诊断和适当治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyroid peroxidase antibody (TPOAb) positivity is prevalent in women of reproductive age and predisposes to thyroid dysfunction, particularly hypothyroidism, which has adverse effects on pregnancy. OBJECTIVE: This study aimed to report the rate of development of abnormal thyroid function among initially euthyroid TPOAb-positive women recruited into the TABLET trial, to identify factors associated with the development of hypothyroidism, and to compare outcomes between euthyroid and treated hypothyroid individuals. METHODS: This observational cohort study, conducted at 49 UK hospitals between 2011 and 2016, included euthyroid TPOAb-positive women 16 to 40 years of age with a history of miscarriage or subfertility, planning pregnancy, randomized to levothyroxine 50 mcg daily or placebo. Abnormal thyroid function, conception rate, and live birth rate (LBR) ≥34 weeks were analyzed. RESULTS: Among the women, 70/940 (7.4%) developed subclinical (SCH) or overt (OH) hypothyroidism: 27/470 taking levothyroxine and 43/470 placebo (relative risk [RR] 0.63; 95% CI, 0.39-1.00; P = 0.05); 83% of cases emerged prepregnancy. Baseline median serum TSH concentrations and TPOAb titers were significantly higher in those who developed hypothyroidism vs those who did not (P < 0.001). Treated SCH/OH demonstrated a higher failure-to-conceive rate compared with euthyroid women (adjusted RR 2.02 [1.56-2.62]; P < 0.001). The LBR ≥ 34 weeks was similar in the treated SCH/OH and euthyroid groups (adjusted RR 1.09 [0.77-1.55]; P = 0.6). CONCLUSION: Approximately 7% of euthyroid TPOAb-positive women will develop hypothyroidism within 1 year preconception or in pregnancy. Conception rates are lower in women with treated SCH/OH compared with euthyroid women, but LBR are comparable. Thyroid function in TPOAb-positive women should be monitored regularly, when trying to conceive, to ensure prompt diagnosis and appropriate treatment initiation.
引用
- Gill S, Cheed V, Morton VAH, et al. Evaluating the Progression to Hypothyroidism in Preconception Euthyroid Thyroid Peroxidase Antibody-Positive Women. J Clin Endocrinol Metab. 2022. PMID: 36103260. doi:10.1210/clinem/dgac525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。